China approves BMS’s hepatitis C drugs
By 
Phillip Broadwith2017-05-04T09:59:00
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
The China Food and Drug Administration (CFDA) has approved two combinations of Bristol-Myers Squibb’s (BMS) hepatitis C medicines. A combination of Daklinza (daclatasvir) with Sunvepra (asunaprevir) has been approved for patients with genotype 1b of the disease, while Daklinza in combination with Gilead’s Sovaldi (sofosbuvir) has been approv